| scholarly article | Q13442814 |
| P50 | author | Thomas E. Starzl | Q1248240 |
| P2093 | author name string | C G Groth | |
| L Brettschneider | |||
| N Kashiwagi | |||
| C O Brantigan | |||
| P2860 | cites work | THE RELATION OF CIRCULATING ANTIBODIES TO SERUM DISEASE. | Q36242962 |
| The use of specific "lymphocyte" antisera to inhibit hypersensitive reactions of the "delayed" type | Q36334374 | ||
| Nature and mode of action of antilymphocytic antiserum | Q36383416 | ||
| The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. | Q37175908 | ||
| Heterologous antilymphocyte glubulin, histoincompatiblity matching, and human renal homotransplantation | Q41440881 | ||
| The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions | Q42043721 | ||
| Application of a microtechnique to viral serological investigations. | Q44916398 | ||
| Studies on heterologous anti-lymphocyte serum in mice. I. In vitro and in vivo properties. | Q47718201 | ||
| Some effects of purified heterologous antihuman lymphocyte serum in man. | Q47821914 | ||
| Effect of Lymphocyte Depletion by Thoracic Duct Fistula and Administration of Antilymphocytic Serum on the Survival of Skin Homografts in Rats | Q59092111 | ||
| Electroimmunodiffusion (EID): a simple, rapid method for quantitation of immunoglobulins in dilute biological fluids | Q70070048 | ||
| Immunosuppressive drugs combined with heterologous anti-lymphocyte serum: a clinical regimen for homograft prolongation | Q71190970 | ||
| [A micro-method of immuno-electrophoresis] | Q73825157 | ||
| STUDIES OF IMMUNE DESTRUCTION OF LYMPHOID TISSUE. I. LYMPHOCYTOTOXIC EFFECT OF RABBIT-ANTI-RAT-LYMPHOCYTE ANTISERUM | Q76703649 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 275-286 | |
| P577 | publication date | 1968-02-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Clinical reactions and serologic changes after the administration of heterologous antilymphocyte globulin to human recipients of renal homografts | |
| P478 | volume | 68 |
| Q40748844 | 100 sibling kidney transplants followed 2 to 7 1/2 years: a multifactorial analysis |
| Q44252884 | A comparative study on the local inflammatory and immunosuppressive activities of anti-mouse anti-lymphocyte sera |
| Q39795275 | A trial with heterologous antilymphocyte globulin in man |
| Q28363261 | Analysis of anesthetic-related morbidity in human recipients of renal homografts |
| Q39915215 | Anti-lymphocyte serum: A review of its immunological effects and therapeutic value |
| Q40013211 | Anti-lymphocytic antibody and autoimmune disease: a review |
| Q71749071 | Antilymphocyte serum blockade of the reticuloendothelial system |
| Q40013355 | Antilymphocytic serum |
| Q39869747 | Antirejection drugs and procedures |
| Q45261023 | Attempt for an induction of immune tolerance against horse IgG in men |
| Q34201776 | Body temperature changes during organ transplantation |
| Q69905037 | Cardiac transplantation |
| Q67312783 | Circulating Immune Complexes, Complement Activation Kinetics and Serum Sickness following Treatment with Heterologous Anti-snake Venom Globulin |
| Q43486303 | Clinical Use of Rabbit Antihuman Lymphocyte Globulin in Cadaver-Kidney Transplantation |
| Q70534661 | Comparison between the effect of rabbit anti-rat lymphocyte sera raised by thymus, thoracic duct, and spleen lymphocytes on second-set tumor allograft in the rat |
| Q66903165 | Comparison of goat ATLG and ASLG in human renal transplants |
| Q47671994 | Cross-reactivity studies of horse, goat and rabbit anti-lymphocyte globulin |
| Q39454949 | Effect of antilyphocyte-globulin potency on survival of cadaver renal transplants. Prospective randomised double-blind trial |
| Q39983755 | Experimental studies relating to the production and clinical testing of anti-human lymphocyte serum |
| Q40945505 | Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula |
| Q69379962 | Glomerular basement membrane-reactive antibodies in anti-lymphocyte sera:in vitro andin vivo characteristics |
| Q34063138 | Glomerular basement membrane—reactive antibody in anti-lymphocyte globulin |
| Q39877218 | Heterologous antilymphocyte globulin |
| Q41440881 | Heterologous antilymphocyte glubulin, histoincompatiblity matching, and human renal homotransplantation |
| Q40751250 | High incidence of horse serum protein allergy in various autoimmune disorders |
| Q47745530 | Homograft Rejection Delayed by Treatment of Donor Tissue in vitro with Antilymphocyte Serum |
| Q47744672 | Human renal allografts. Glomerular deposits of horse immunoglobulin G and nephritis following administration of antilymphocyte globulin |
| Q69374926 | Humoral responses in human organ transplantation |
| Q41271458 | Improvements in the preparation of heterologous antilymphocyte globulin with special reference to absorption and diethylaminoethyl cellulose batch production. |
| Q53740337 | Intensive immunosuppression in the treatment of multiple sclerosis. |
| Q39987308 | Kidney Transplantation: Patient Selection and Management |
| Q40763260 | Long-term therapy using horse anti-dog lymphocyte globulin without sensitization against horse protein |
| Q67291929 | Occurrence of ANTI-AHLG in renal transplant patients on AHLG (anti-human lymphocyte globulin) |
| Q34275572 | Organ transplantation, past and present |
| Q38540105 | Orthotopic homotransplantation of the human liver |
| Q58972756 | Prevention of Rapid Immune Elimination of Anti-lymphocytic Globulin in Transplant Patients |
| Q93699958 | Reversal of acute clinical and experimental organ rejection using large doses of intravenous prednisolone |
| Q33471388 | Reversible thrombopenia in the clinical use of antilymphocyte serum |
| Q33467450 | Selected topics on antilymphocyte serum |
| Q93683032 | Serum sickness |
| Q37396491 | Shwartzman reaction after human renal homotransplantation |
| Q41845547 | THE USE OF HETEROLOGOUS ANTILYMPHOCYTE GLOBULIN (ALG) IN HUMAN RENAL AND LIVER TRANSPLANTATION |
| Q93735201 | The antigenic and immunosuppressive properties of normal and antilymphocytic equine IgG subfractions |
| Q71420421 | The effect of antilymphocyte serum alone or in combination with a cytostatic agent on mouse leukemia |
| Q83629646 | The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients |
| Q39907124 | The future of transplantation immunology. |
| Q40926742 | The intravenous administration of equine antilymphocytic globulin in renal transplant recipients and the detection of circulating antibodies to equine globulin |
| Q69374722 | The reduction of antigenicity of heterologous antilymphocyte serum with acid Taka-protease |
| Q40911721 | The risk of ALG therapy possible side effects: prevention and treatment (author's transl) |
| Q72194444 | The suppression of experimental thyroiditis in the rat by heterologous anti-lymphocyte globulin |
| Q54961646 | Use of antilymphocyte globulin after cadaveric renal transplantation |
| Q93826344 | [Serologic studies of patients under treatment with xenogenous antilymphocyte globulin] |
Search more.